| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1048130718 |
| P356 | DOI | 10.1038/NG.2806 |
| P698 | PubMed publication ID | 24185513 |
| P5875 | ResearchGate publication ID | 258253237 |
| P50 | author | Puangrat Yongvanit | Q84104218 |
| Dan Duda | Q102108054 | ||
| Choon Kiat Ong | Q40793543 | ||
| Paiboon Sithithaworn | Q42924138 | ||
| Pierce Chow | Q43282371 | ||
| Bin Tean Teh | Q47451223 | ||
| Steven G. Rozen | Q55711532 | ||
| Dachuan Huang | Q59544782 | ||
| P2093 | author name string | Patrick Tan | |
| Irinel Popescu | |||
| Sopit Wongkham | |||
| Simona Dima | |||
| Chawalit Pairojkul | |||
| Narong Khuntikeo | |||
| Ioana Cutcutache | |||
| Ser Yee Lee | |||
| Kiat Hon Lim | |||
| Peng Chung Cheow | |||
| Su Pin Choo | |||
| Shenli Zhang | |||
| John R McPherson | |||
| Alexander Chung | |||
| Waraporn Chan-On | |||
| Anca Nastase | |||
| Iain Bee Huat Tan | |||
| Swe Swe Myint | |||
| Maarja-Liisa Nairismägi | |||
| Cedric Chuan Young Ng | |||
| Vikneswari Rajasegaran | |||
| Weng Khong Lim | |||
| Apinya Jusakul | |||
| Hong Lee Heng | |||
| Sanjanaa Nagarajan | |||
| Anna Gan | |||
| Bernice Huimin Wong | |||
| London Ooi | |||
| Priya Vohra | |||
| Vajaraphongsa Bhudhisawasdi | |||
| Willie Yu | |||
| P2860 | cites work | Largest subunits of the human SWI/SNF chromatin-remodeling complex promote transcriptional activation by steroid hormone receptors | Q24305418 |
| Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB | Q24309403 | ||
| Molecular architecture of quartet MOZ/MORF histone acetyltransferase complexes | Q24312967 | ||
| Cancer-associated IDH1 mutations produce 2-hydroxyglutarate | Q24320239 | ||
| BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization | Q24337105 | ||
| Frequent mutation of BAP1 in metastasizing uveal melanomas | Q24601069 | ||
| Core signaling pathways in human pancreatic cancers revealed by global genomic analyses | Q24606006 | ||
| Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas | Q24610836 | ||
| The tumorigenic liver fluke Opisthorchis viverrini--multiple pathways to cancer | Q24612587 | ||
| Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases | Q24632807 | ||
| Infection with liver flukes (Opisthorchis viverrini, Opisthorchis felineus and Clonorchis sinensis) | Q72152035 | ||
| Exome sequencing of liver fluke-associated cholangiocarcinoma | Q84073724 | ||
| Fast and accurate short read alignment with Burrows-Wheeler transform | Q24653853 | ||
| Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies | Q27002547 | ||
| Linear models and empirical bayes methods for assessing differential expression in microarray experiments | Q27860758 | ||
| The Sequence Alignment/Map format and SAMtools | Q27860966 | ||
| ARID1A mutations in cancer: another epigenetic tumor suppressor? | Q28280605 | ||
| Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma | Q28292742 | ||
| Patterns of somatic mutation in human cancer genomes | Q29547841 | ||
| Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation | Q29615366 | ||
| IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype | Q29617457 | ||
| TumorBoost: normalization of allele-specific tumor copy numbers from a single pair of tumor-normal genotyping microarrays | Q33576281 | ||
| Cholangiocarcinoma: lessons from Thailand | Q34034208 | ||
| IMA: an R package for high-throughput analysis of Illumina's 450K Infinium methylation data | Q34130053 | ||
| Allele-specific copy number analysis of tumors | Q34165640 | ||
| The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma | Q34190027 | ||
| Analysis of the ARMD1 locus: evidence that a mutation in HEMICENTIN-1 is associated with age-related macular degeneration in a large family | Q34271490 | ||
| BAP1 loss defines a new class of renal cell carcinoma | Q34280223 | ||
| Microproteinuria during Opisthorchis viverrini infection: a biomarker for advanced renal and hepatobiliary pathologies from chronic opisthorchiasis | Q34746708 | ||
| Risk factors for cholangiocarcinoma | Q35074664 | ||
| Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping | Q35705307 | ||
| The epidemiology of cholangiocarcinoma | Q35802314 | ||
| Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment | Q36900063 | ||
| A single-array preprocessing method for estimating full-resolution raw copy numbers from all Affymetrix genotyping arrays including GenomeWideSNP 5 & 6. | Q37324776 | ||
| SWI/SNF nucleosome remodellers and cancer. | Q37886668 | ||
| Genomic profiles specific to patient ethnicity in lung adenocarcinoma | Q39756938 | ||
| Regulation of intracellular pH by immortalized human intrahepatic biliary epithelial cell lines | Q41464352 | ||
| Angelman syndrome and severe infections in a patient with de novo 15q11.2-q13.1 deletion and maternally inherited 2q21.3 microdeletion | Q41933098 | ||
| Deletions of IKZF1 and SPRED1 are associated with poor prognosis in a population-based series of pediatric B-cell precursor acute lymphoblastic leukemia diagnosed between 1992 and 2011. | Q50860875 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1474-1478 | |
| P577 | publication date | 2013-11-03 | |
| P1433 | published in | Nature Genetics | Q976454 |
| P1476 | title | Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers | |
| P478 | volume | 45 |
| Q39160195 | A comparative proteomic analysis of bile for biomarkers of cholangiocarcinoma |
| Q39769621 | A novel mouse model of intrahepatic cholangiocarcinoma induced by liver-specific Kras activation and Pten deletion |
| Q42465699 | A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma |
| Q92029585 | Absence of an embryonic stem cell DNA methylation signature in human cancer |
| Q39673531 | Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference |
| Q26784091 | An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of Cholangiocarcinoma |
| Q35949450 | Anti-Tumor Effects of Second Generation β-Hydroxylase Inhibitors on Cholangiocarcinoma Development and Progression. |
| Q57112122 | Aspartate beta-hydroxylase promotes cholangiocarcinoma progression by modulating RB1 phosphorylation |
| Q57283068 | BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1/2 and JNK/c-Jun pathways |
| Q28397624 | BAP1 hereditary cancer predisposition syndrome: a case report and review of literature |
| Q41752870 | BRCA1-associated protein 1 (BAP1) deubiquitinase antagonizes the ubiquitin-mediated activation of FoxK2 target genes |
| Q43058864 | Biliary epithelial injury-induced regenerative response by IL-33 promotes cholangiocarcinogenesis from peribiliary glands |
| Q64101426 | Biliary tract cancers: current knowledge, clinical candidates and future challenges |
| Q89653705 | Biomarkers for hepatobiliary cancers |
| Q30378139 | CD44 variant-dependent redox status regulation in liver fluke-associated cholangiocarcinoma: A target for cholangiocarcinoma treatment. |
| Q34499647 | CRISPR/Cas9 somatic multiplex-mutagenesis for high-throughput functional cancer genomics in mice |
| Q38740975 | Cadherin-6 is a putative tumor suppressor and target of epigenetically dysregulated miR-429 in cholangiocarcinoma |
| Q54127911 | Cancer Genomics and Biology 2015 – Meeting Report. |
| Q46087686 | Cholangiocarcinoma - evolving concepts and therapeutic strategies |
| Q96817624 | Cholangiocarcinoma 2020: the next horizon in mechanisms and management |
| Q53224958 | Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients. |
| Q28076098 | Cholangiocarcinoma: Current Knowledge and New Developments |
| Q60300564 | Cholangiocarcinoma: a guide for the nonspecialist |
| Q34959174 | Cholangiocarcinoma: molecular pathways and therapeutic opportunities |
| Q92284317 | Chromatin remodeling mediated by ARID1A is indispensable for normal hematopoiesis in mice |
| Q38571961 | Clonorchiasis |
| Q50967762 | Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets. |
| Q28397229 | Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases |
| Q26747432 | Control of Wnt Receptor Turnover by R-spondin-ZNRF3/RNF43 Signaling Module and Its Dysregulation in Cancer |
| Q61865585 | DLEC1 methylation is associated with a better clinical outcome in patients with intrahepatic cholangiocarcinoma of the small duct subtype |
| Q31120836 | Data on affected cancer-related genes in pediatric t(12;21)-positive acute lymphoblastic leukemia patients harboring unbalanced der(6)t(X;6) translocations |
| Q91938819 | Dependency of Cholangiocarcinoma on Cyclin D-Dependent Kinase Activity |
| Q40875509 | Derived neutrophil lymphocyte ratio may predict benefit from cisplatin in the advanced biliary cancer: the ABC-02 and BT-22 studies |
| Q48138303 | Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers. |
| Q37642847 | Elevated prevalence of Helicobacter species and virulence factors in opisthorchiasis and associated hepatobiliary disease |
| Q57111762 | Emergence of Intrahepatic Cholangiocarcinoma: How High-Throughput Technologies Expedite the Solutions for a Rare Cancer Type |
| Q47941750 | Emerging Opportunities for Target Discovery in Rare Cancers |
| Q38642455 | Emerging molecular targets and therapy for cholangiocarcinoma |
| Q39227356 | Emerging molecular therapeutic targets for cholangiocarcinoma |
| Q104802880 | Emerging role of SWI/SNF complex deficiency as a target of immune checkpoint blockade in human cancers |
| Q52665942 | Epithelial Transforming Growth Factor-β Signaling Does Not Contribute to Liver Fibrosis but Protects Mice From Cholangiocarcinoma. |
| Q64889563 | Establishment of Highly Transplantable Cholangiocarcinoma Cell Lines from a Patient-Derived Xenograft Mouse Model. |
| Q50128422 | Establishment of cholangiocarcinoma cell lines from patients in the endemic area of liver fluke infection in Thailand |
| Q34429754 | Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma. |
| Q38812588 | Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). |
| Q38530342 | Exploring the Mechanisms of Gastrointestinal Cancer Development Using Deep Sequencing Analysis. |
| Q36860098 | Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer |
| Q26824969 | Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma |
| Q36884411 | Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise |
| Q92486905 | Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review |
| Q38614249 | Functional and genetic deconstruction of the cellular origin in liver cancer. |
| Q39022105 | Gene alterations and epigenetic changes in intrahepatic cholangiocarcinoma |
| Q55523920 | Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma. |
| Q40979031 | Genetic alterations in Japanese extrahepatic biliary tract cancer. |
| Q98159763 | Genetic analysis in the clinical management of biliary tract cancer |
| Q26852049 | Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies |
| Q26751655 | Genetic profiling of intrahepatic cholangiocarcinoma and its clinical implication in targeted therapy |
| Q44899728 | Genetics: genetics of biliary tract cancer |
| Q47248421 | Genomic Perturbations Reveal Distinct Regulatory Networks in Intrahepatic Cholangiocarcinoma |
| Q34540948 | Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice |
| Q37743503 | Genomic and proteomic characterization of ARID1A chromatin remodeller in ampullary tumors |
| Q38188515 | Genomic and transcriptional alterations of cholangiocarcinoma |
| Q92567536 | Genomic characterization of cholangiocarcinoma in primary sclerosing cholangitis reveals novel therapeutic opportunities |
| Q41262209 | Genomic landscapes of breast fibroepithelial tumors |
| Q30405398 | Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets |
| Q53390123 | Genomic spectra of biliary tract cancer. |
| Q37017110 | Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design |
| Q38700344 | Germline BAP1 mutations induce a Warburg effect |
| Q38921406 | Helminth infection-induced malignancy |
| Q35841658 | Hepatocyte-Specific Arid1a Deficiency Initiates Mouse Steatohepatitis and Hepatocellular Carcinoma. |
| Q47655313 | Hypermutation and microsatellite instability in gastrointestinal cancers |
| Q28828382 | Hypermutation and unique mutational signatures of occupational cholangiocarcinoma in printing workers exposed to haloalkanes |
| Q42594611 | IDH mutations in liver cell plasticity and biliary cancer |
| Q47645620 | Identification of MALT1 as both a prognostic factor and a potential therapeutic target of regorafenib in cholangiocarcinoma patients. |
| Q90706172 | Identification of candidate genes for the diagnosis and treatment of cholangiocarcinoma using a bioinformatics approach |
| Q92244861 | Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma |
| Q92354127 | Immune Therapy for Liver Cancers |
| Q38703148 | Immunotherapeutic Approaches to Biliary Cancer |
| Q90919779 | Integrative Analysis Defines Distinct Prognostic Subgroups of Intrahepatic Cholangiocarcinoma |
| Q57261202 | Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles |
| Q32173000 | Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles |
| Q40467070 | Intrahepatic cholangiocarcinoma frequently shows loss of BAP1 and PBRM1 expression, and demonstrates specific clinicopathological and genetic characteristics with BAP1 loss. |
| Q99727865 | Intrahepatic cholangiocarcinomas with IDH1/2 mutation-associated hypermethylation at selective genes and their clinicopathological features |
| Q37716471 | Intratumoral heterogeneity of intrahepatic cholangiocarcinoma |
| Q33763540 | Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma |
| Q58728288 | Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma to the BET inhibitor JQ1 |
| Q37525776 | Jagged 1 is a major Notch ligand along cholangiocarcinoma development in mice and humans |
| Q52593254 | L1 retrotransposition is a common feature of mammalian hepatocarcinogenesis. |
| Q88929581 | Landscape of Microsatellite Instability Across 39 Cancer Types |
| Q41670848 | Liver Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells |
| Q35913384 | Liver cancer oncogenomics: opportunities and dilemmas for clinical applications |
| Q51687417 | Loss of ARID1A Expression Presents a Novel Pathway of Carcinogenesis in Biliary Carcinomas. |
| Q35959422 | Loss of BAP1 Expression Is Very Rare in Pancreatic Ductal Adenocarcinoma |
| Q28384496 | Loss of BAP1 Expression Occurs Frequently in Intrahepatic Cholangiocarcinoma |
| Q58612052 | Loss of BAP1 expression is associated with genetic mutation and can predict outcomes in gallbladder cancer |
| Q64062084 | Low frequency of mismatch repair deficiency in gallbladder cancer |
| Q26776098 | Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics |
| Q38917883 | Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma |
| Q58086865 | Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma |
| Q92353488 | Molecular characterization of localized pleural mesothelioma |
| Q35592221 | Molecular diagnosis of intrahepatic cholangiocarcinoma |
| Q38244965 | Molecular pathogenesis of intrahepatic cholangiocarcinoma |
| Q39120148 | Molecular profiling of intrahepatic cholangiocarcinoma: the search for new therapeutic targets |
| Q92029922 | Molecular targets in cholangiocarcinoma |
| Q35183964 | Moving upstream in the war on WNTs. |
| Q33757122 | Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups |
| Q64234397 | Murine Liver Organoids as a Genetically Flexible System to Study Liver Cancer and |
| Q91891453 | Mutant IDH1 confers resistance to energy stress in normal biliary cells through PFKP-induced aerobic glycolysis and AMPK activation |
| Q33772624 | Mutation signatures of carcinogen exposure: genome-wide detection and new opportunities for cancer prevention |
| Q48000860 | Mutational landscape of combined hepatocellular carcinoma and cholangiocarcinoma, and its clinicopathological significance |
| Q54300991 | Mutational landscape of intrahepatic cholangiocarcinoma. |
| Q30665308 | Mutational landscapes of tongue carcinoma reveal recurrent mutations in genes of therapeutic and prognostic relevance. |
| Q33600399 | Mutations of Chromatin Structure Regulating Genes in Human Malignancies |
| Q47419818 | Mutations of candidate tumor suppressor genes at chromosome 3p in intrahepatic cholangiocarcinoma |
| Q92190812 | Neglected Agent Eminent Disease: Linking Human Helminthic Infection, Inflammation, and Malignancy |
| Q97067801 | New Analysis Framework Incorporating Mixed Mutual Information and Scalable Bayesian Networks for Multimodal High Dimensional Genomic and Epigenomic Cancer Data |
| Q38619219 | New Horizons for Precision Medicine in Biliary Tract Cancers |
| Q50050635 | New insights into cholangiocarcinoma: multiple stems and related cell lineages of origin. |
| Q40633762 | Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance |
| Q94521075 | Oncogenic driver genes and tumor microenvironment determine the type of liver cancer |
| Q35016411 | Oxidative stress and its significant roles in neurodegenerative diseases and cancer |
| Q38646960 | Pancreatic intraductal tubulopapillary neoplasm is genetically distinct from intraductal papillary mucinous neoplasm and ductal adenocarcinoma |
| Q28067519 | Parasite Infection, Carcinogenesis and Human Malignancy |
| Q36014376 | Pathological characteristics of intraductal polypoid neoplasms of bile ducts in Thailand |
| Q35215602 | Patterns of chromosomal copy-number alterations in intrahepatic cholangiocarcinoma |
| Q55662464 | Peribiliary Glands as the Cellular Origin of Biliary Tract Cancer. |
| Q39453553 | Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies |
| Q50545897 | RNF43 mutation frequently occurs with GNAS mutation and mucin hypersecretion in intraductal papillary neoplasms of the bile duct. |
| Q37670693 | Receptor tyrosine kinase amplification is predictive of distant metastasis in patients with oral squamous cell carcinoma |
| Q91737464 | Receptor-Interacting Protein Kinase 1 Promotes Cholangiocarcinoma Proliferation And Lymphangiogenesis Through The Activation Protein 1 Pathway |
| Q33752609 | Roles of deletion of Arid1a, a tumor suppressor, in mouse ovarian tumorigenesis |
| Q45011155 | STATs profiling reveals predominantly-activated STAT3 in cholangiocarcinoma genesis and progression |
| Q34763466 | Schistosome and liver fluke derived catechol-estrogens and helminth associated cancers |
| Q55363407 | Sequencing of intraductal biopsies is feasible and potentially impacts clinical management of patients with indeterminate biliary stricture and cholangiocarcinoma. |
| Q36092850 | Somatic alteration and depleted nuclear expression of BAP1 in human esophageal squamous cell carcinoma |
| Q91657327 | Somatic mutation signatures in primary liver tumors of workers exposed to ionizing radiation |
| Q38849599 | Sulfated Galactans from Red Seaweed Gracilaria fisheri Target EGFR and Inhibit Cholangiocarcinoma Cell Proliferation |
| Q39998931 | Suppression of the SWI/SNF Component Arid1a Promotes Mammalian Regeneration |
| Q39498232 | Synergistic effects of isomorellin and forbesione with doxorubicin on apoptosis induction in human cholangiocarcinoma cell lines |
| Q36790108 | TGFβ signaling: a friend or a foe to hepatic fibrosis and tumorigenesis |
| Q30398807 | Targeting Angiogenesis in Biliary Tract Cancers: An Open Option |
| Q34505489 | The Chromatin Regulator BRPF3 Preferentially Activates the HBO1 Acetyltransferase but Is Dispensable for Mouse Development and Survival |
| Q58792806 | The Curious Case of Cholangiocarcinoma: Opportunities for Environmental Health Scientists to Learn about a Complex Disease |
| Q50350640 | The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer |
| Q38195175 | The emerging roles of ARID1A in tumor suppression |
| Q38982367 | The genomic landscape of nasopharyngeal carcinoma |
| Q92502920 | The importance of including diverse populations in cancer genomic and epigenomic studies |
| Q38776213 | The inflammatory inception of gallbladder cancer |
| Q26751224 | The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets |
| Q33656860 | The potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer |
| Q38823884 | The potential role of liver stem cells in initiation of primary liver cancer |
| Q28074145 | The rise of the FGFR inhibitor in advanced biliary cancer: the next cover of time magazine? |
| Q35818437 | The role of intracellular calcium for the development and treatment of neuroblastoma |
| Q37628969 | Therapeutic implication of HER2 in advanced biliary tract cancer |
| Q99352179 | Therapy of Primary Liver Cancer |
| Q36080191 | Tissue Microbiome Profiling Identifies an Enrichment of Specific Enteric Bacteria in Opisthorchis viverrini Associated Cholangiocarcinoma |
| Q50211222 | Towards Personalized Medicine for Intrahepatic Cholangiocarcinoma: Pharmacogenomic Stratification of Patients |
| Q37269146 | Two classes of intrahepatic cholangiocarcinoma defined by relative abundance of mutations and copy number alterations |
| Q41113380 | Von Hippel-Lindau status influences phenotype of liver cancers arising from PTEN loss. |
| Q38908764 | WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited |
| Q40151513 | Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma. |
| Q50967175 | Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity. |
| Q36310498 | Why does infection with some helminths cause cancer? |
| Q51518956 | Wnt signaling in cancer. |
| Q64935548 | YAP and the Hippo pathway in cholangiocarcinoma. |
Search more.